Addressing large and growing unmet needs

89bio is a clinical-stage biopharmaceutical company focused on rapidly advancing our lead product candidate, BIO89-100, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH). BIO89-100 is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It may be a differentiated FGF21 therapy, and we believe it has the potential to become a mainstay of therapy for NASH given its ability to address the key liver pathologies (steatosis and fibrosis) and underlying metabolic dysregulation in patients with NASH. We are also expanding the breadth of indications for BIO89-100 with an initial focus on severe hypertriglyceridemia (SHTG).

Management

Rohan Palekar
CEO
Ram Waisbourd
Chief Operating Officer and
Chief Business Officer
Dr. Hank Mansbach
Chief Medical Officer
Quoc Le-Nguyen
Chief Technical Operations Officer and
Head of Quality
Ryan Martins
Chief Financial Officer

Board of Directors

Dr. Steven Altschuler (Chairman)
Managing Director, Ziff Capital Partners
Anat Naschitz
Managing Director, OrbiMed
Dr. Greg Grunberg
Managing Director, Longitude Capital
Derek DiRocco, PhD
Principal, RA Capital Management
Dr. Michael Hayden
CM, BC, MBChB, PhD, FRCP(C), FRSC
Rohan Palekar
CEO